{"groups":[{"description":"Hyperfractionated total body irradiation to a dose of 1375-1500 cGy (depending on age, stage of disease and requirement of general anesthesia) with lung shielding) Thiotepa (5 mg/kg/day x 2 or 10 mg/kg/day x 1) Cyclophosphamide (60 mg/kg/day x 2) (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)\n\ntotal body irradiation: dose of 1375-1500 cGy\n\nThiotepa: 5 mg/kg/day x 2 or 10 mg/kg/day x 1\n\nCyclophosphamide: 60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).\n\n(CliniMACS) T-cell depleted PBSC Transplant","id":"FG000","title":"Total Body Irradiation, Thiotepa and Cyclophosphamide"},{"description":"Busulfan (0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified according to pharmacokinetics Melphalan (70mg/m2/day x 2 ) Fludarabine (25mg/m2/ day x 5)\n\nBusulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics\n\nMelphalan: 70mg/m2/day x 2\n\nFludarabine: 25mg/m2/ day x 5\n\n(CliniMACS) T-cell depleted PBSC Transplant","id":"FG001","title":"Busulfan, Melphalan and Fludarabine"},{"description":"Clofarabine (20mg/m2/ day x 5) (or, for children \\<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval), Melphalan (70 mg/m2/day x 2) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)\n\nThiotepa: 5 mg/kg/day x 2 or 10 mg/kg/day x 1\n\nMelphalan: 70mg/m2/day x 2\n\nClofarabine: 20mg/m2/ day x 5 (or, for children \\<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)\n\n(CliniMACS) T-cell depleted PBSC Transplant","id":"FG002","title":"Clofarabine, Melphalan and Thiotepa"},{"description":"Melphalan (70 mg/m2/day x 2) Fludarabine (25mg/m2/ day x 5 ) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)\n\nThiotepa: 5 mg/kg/day x 2 or 10 mg/kg/day x 1\n\nMelphalan: 70mg/m2/day x 2\n\n(CliniMACS) T-cell depleted PBSC Transplant","id":"FG003","title":"Melphalan, Fludarabine and Thiotepa"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Concern regarding adequacy of transplant cell dose"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Relapse identified before transplant"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Intercurrent medication condition rendered patient ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Relapse identified before transplant"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"132","numUnits":"1"},{"groupId":"FG001","numSubjects":"227","numUnits":"0"},{"groupId":"FG002","numSubjects":"52","numUnits":"1"},{"groupId":"FG003","numSubjects":"11","numUnits":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"125","numUnits":"1"},{"groupId":"FG001","numSubjects":"213","numUnits":"0"},{"groupId":"FG002","numSubjects":"52","numUnits":"1"},{"groupId":"FG003","numSubjects":"11","numUnits":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7","numUnits":"0"},{"groupId":"FG001","numSubjects":"14","numUnits":"0"},{"groupId":"FG002","numSubjects":"0","numUnits":"0"},{"groupId":"FG003","numSubjects":"0","numUnits":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"2 patients received 2 separate transplants on each Arm A and C","typeUnitsAnalyzed":"Additional Transplant"}